Using a modified poliovirus to enhance cancer immunotherapy
Official title: Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy
Funded at Duke University · NIH-10895543 · Data updated 2026-11-12
This study is looking at how a special version of the poliovirus can help boost your immune system to better fight cancer by targeting important immune cells, and it could offer a new way to improve cancer treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 28, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $358,773 |
| NIH project number | 5R01CA281320-02 |
| Project ID | NIH-10895543 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that may benefit from enhanced immune responses, particularly those involving dendritic cell interactions.
✕Less likely to help
Patients with non-cancerous conditions or those whose tumors do not involve the immune mechanisms targeted by this research may not benefit.
What this research studies
This research investigates how a modified poliovirus can be used to improve the immune system's ability to fight cancer. It focuses on a specific type of immune cell, called dendritic cells, which are crucial for presenting tumor antigens to other immune cells. By using a safe version of the poliovirus that targets these dendritic cells, the study aims to stimulate a stronger immune response against tumors. Patients may benefit from this innovative approach to immunotherapy that seeks to overcome challenges in cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that harness the body's immune system to target and destroy tumors.
How similar studies have gone: Previous research has shown promise in using viral vectors for immunotherapy, indicating that this approach may be viable and effective.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Gromeier, Matthias — Duke University
- Study coordinator: Gromeier, Matthias
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.